Mynd life sciences announces successful conclusion of debenture settlement agreement and leadership transition

Vancouver, british columbia--(newsfile corp. - january 10, 2025) - mynd life sciences (cse: mynd) (otc pink: myndf) ("mynd" or the "company") a clinical-stage life sciences company committed to the development and commercialization of a biomarker tool for monitoring depression, today announced that the application to end its debenture has been successfully accepted by both the debenture holders and the regulatory commission. this announcement confirms the removal of $3.5 million (cdn) of debt from its balance sheet.
MYND Ratings Summary
MYND Quant Ranking